04 / 09 / 2018
The Lancet has published key results from HPTN 074

The Lancet has published an article co-authored by UIPHP researchers, which presents key results from HPTN 074 - controlled trial conducted among people who inject drugs in Ukraine, Indonesia and Vietnam. In Ukraine, the project was implemented by the Ukrainian Institute on Public Health Policy in cooperation with the L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases and the NGO “Aeneas Club”.

The HPTN 074 study evaluated an integrated intervention combining psychosocial counseling and supported referrals for antiretroviral therapy in any type of CD4 cell count and substance use treatment for people living with HIV who inject drugs compared to locally available standard care.

Overall, 502 people living with HIV and 806 people who were injected with drugs entered the study over 15 months. The median age was 35 years. Eighty-five percent of the participants enrolled were men; most of the women who participated in the study were enrolled in Ukraine.

At week 26, intervention arm participants were twice as likely to report antiretroviral therapy in comparison with the standard care arm participants and twice as likely to achieve undetectable virus load. The effects persisted at week 52. Among the intervention arm participants at week 52, self-reported substance use treatment was higher than the standard care arm participants.

A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study

William C Miller; Irving F Hoffman; Brett S Hanscom; Tran V Ha; Kostyantyn Dumchev; Zubairi Djoerban; Scott M Rose; Carl A Latkin; David S Metzger; Kathryn E Lancaster; Vivian F Go; Sergii Dvoriak; Katie R Mollan; Sarah A Reifeis; Estelle M Piwowar-Manning; Paul Richardson; Michael G Hudgens; Erica L Hamilton; Jeremy Sugarman; Susan H Eshleman; Hepa Susami; Viet Anh Chu; Samsuridjal Djauzi; Tetiana Kiriazova; Duong D Bui; Steffanie A Strathdee; David N Burns

The Lancet. September 01, 2018 (EN)


HPTN 074 is funded by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), and the U.S. National Institute on Drug Abuse (NIDA), both part of the U. S. National Institutes of Health (NIH).